Because GHK-Cu is researched for regenerative, tissue-remodeling, collagen-related, and cellular-signaling pathways, research involving active or suspected malignancies, copper-metabolism conditions, liver-related investigations, or complex dermatological research models may warrant additional monitoring and individualized evaluation
It is not a drug, supplement, or food product
We believe that transparency is the foundation of trust
GLP-1 receptor agonists reduce inflammation in the brain and the protein-deposit changes characteristic of Alzheimer's disease in animal models, and early-stage clinical trials of older drugs in the same class have produced suggestions of preservation of cognitive function in mild memory and thinking problems and in Parkinson's disease, although large-scale confirmation is still not there [13]
Much more research is needed